

Technology Appraisal Committee D Interests Register

Topic: Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

Publication Date: 10/08/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor James Catto	Clinical expert	Direct- financial	Professor Catto has received funding from BMS for advisory boards and to run a half day teaching course for BMS staff.	N/A	09.03.2021	N/A	It was agreed that his declaration would not prevent Professor Catto from providing expert advice to the committee
Kevin Gorman	Patient expert	Indirect- financial	Action Bladder Cancer UK received donations of £16,000 during the last 12 months from BMS.	N/A	12.05.2021	N/A	It was agreed that his declaration would not prevent Kevin from providing expert advice to the committee
Professor Syed Hussain	Clinical expert	Direct- financial	Professor Hussain has received advisory board/consultancy fees from: Roche, MSD, AstraZeneca, BMS, Janssen, Astellas, Bayer, Pierre Fabre, Sotio, GSK, Ipsen, Eisai, and research funding from: CR UK, MRC/NIHR, UHB charities, CCC charities, North West Cancer Research, Yorkshire Cancer research, Bayer, Janssen, Boehringer	N/A	09.03.2021	N/A	It was agreed that his declaration would not prevent Professor Hussain from providing expert advice to the committee

			Ingelheim, Pierre Fabre, Eli Lilly.				
Dr Lydia Makaroff	Patient expert Employee of Fight Bladder Cancer Volunteer board member of the World Bladder Cancer Patient Coalition	Indirect- financial	Fight Bladder Cancer has received financial support from Roche, AstraZeneca, Arquer, Bayer, Astellas, Bristol-Myers Squibb, Ferring, Ipsen, Janssen, Merck, MSD, Olympus, Pfizer, Photocure, Prokarium, Sanofi, and SeaGen. World Bladder Cancer Patient Coalition has received financial support Roche, AstraZeneca, Bayer, Astellas, Bristol-Myers Squibb, Ipsen, Janssen, Merck, MSD, Pfizer, Photocure, and SeaGen.	N/A	02.03.2021	N/A	It was agreed that her declaration would not prevent Dr Makaroff from providing expert advice to the committee.